# Program 60: Cancer Risk, Prevention, and Early Detection

> **NIH NIH P30** · DANA-FARBER CANCER INST · 2024 · $40,758

## Abstract

Cancer Risk, Prevention, and Early Detection Program
Project Summary / Abstract
The mission of the Cancer Risk, Prevention, and Early Detection (CaRPED) Program is to decrease the
burden of cancer by (a) focusing a broad array of research around the critical period of cancer initiation and
early growth, and (b) devising clinically effective strategies to intercept this process among people at risk. The
Program’s scope ranges from the general population to high-risk groups to individuals with pre-cancerous
lesions or targetable mutations.
CaRPED is a new Program that evolved from a previous Program in Cancer Risk and Disparities (CaRD). Its
mission relies on leveraging DF/HCC expertise in cancer biology, epidemiology, prevention, and the science of
implementation, together with the breadth and depth of the Boston ecosystem for technological innovation. The
Program is committed to the translation of scientific advances and the dissemination of knowledge into
sustainable community-based practices as well as the alleviation of cancer-related disparities. Training a new
generation of researchers with transdisciplinary, quantitative, clinical, technological, and implementation skills
is an important Program focus.
Our 86 members (55 primary and 31 secondary) represent all seven DF/HCC institutions and 17 academic
departments. In 2019, peer-reviewed grant funding attributed to the Program was $5.7 million in direct costs
from the NCI and $6.7 million from other sponsors. During the current funding period, primary CaRPED
members published 914 cancer-relevant papers. Of these, 23% were inter-institutional, 9% were intra-
programmatic, and 43% were inter-programmatic collaborations between two or more DF/HCC members.
These numbers reflect the breadth of inter-Program interactivity stewarded by Program and senior DF/HCC
leaders in close alignment with the Cancer Center’s strategic plan.
For the next CCSG funding period, the Program’s Specific Aims are to 1) develop and validate new
technologies for pre-cancer and early cancer detection, 2) develop personalized and precision approaches for
cancer interception using new technologies for risk assessment and pre-cancer and early cancer detection,
and 3) apply personalized and precision approaches for cancer interception through multidisciplinary teams.
DF/HCC’s extensive infrastructure for transdisciplinary collaboration, innovative clinical trials, community
engagement, shared resources, education, and training will be instrumental in achieving these concrete goals.

## Key facts

- **NIH application ID:** 10768680
- **Project number:** 5P30CA006516-59
- **Recipient organization:** DANA-FARBER CANCER INST
- **Principal Investigator:** SAPNA SYNGAL
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $40,758
- **Award type:** 5
- **Project period:** 1997-03-10 → 2026-11-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10768680

## Citation

> US National Institutes of Health, RePORTER application 10768680, Program 60: Cancer Risk, Prevention, and Early Detection (5P30CA006516-59). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10768680. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*